Bravecto Dog 1400mg x 1tb (40-56kg)

Bravecto – external antiparasitic for dogs in chewable tablet form

Indications:

For the treatment of tick and flea infestations in dogs.

This veterinary medicinal product is a systemic insecticide and acaricide that provides:

immediate and persistent flea killing activity (Ctenocephalides felis) for 12 weeks,
immediate and persistent tick killing activity for 12 weeks for Ixodes ricinus, Dermacentor reticulatus and D. variabilis
immediate and persistent tick killing activity for 8 weeks for Rhiphicephalus sanguineus.
Fleas and ticks must be attached to the host and feed in order to be exposed to the active substance. The onset of effect is 8 hours after attachment for fleas (C. felis) and 12 hours after attachment for ticks (I. ricinus).

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Each chewable tablet contains:

Bravecto chewable tablet Fluralaner (mg)

For very small dogs (2-4.5 kg) 112.5

For small dogs (>4.5-10 kg) 250

For medium dogs (>10-20 kg) 500

For large dogs (>20-40 kg) 1,000

For very large dogs (>40-56 kg) 1,400

Tablets of various shades of brown with smooth or slightly rough surface and circular shape. Some marbling, spots or both may be present.

Contraindications: Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Adverse reactions:

The most common adverse reactions observed in clinical trials (1.6% of dogs treated) were mild and transient gastrointestinal effects such as diarrhoea, vomiting, inappetence and salivation.

The frequency of adverse reactions is defined using the following convention:

– very common (more than 1 in 10 animals displaying adverse reactions during one treatment)

– common (more than 1 but less than 10 animals in 100 animals)

– uncommon (more than 1 but less than 10 animals in 1,000 animals)

– rare (more than 1 but less than 10 animals in 10,000 animals)

– very rare (less than 1 animal in 10,000 animals, including isolated reports)

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

Target species: Dogs.

Models:

Bravecto 112.5 mg chewable tablets for very small dogs (2-4.5 kg)
Bravecto 250 mg chewable tablets for small dogs (>4.5-10 kg)
Bravecto 500 mg chewable tablets for medium dogs (>10-20 kg)
Bravecto 1000 mg chewable tablets for large dogs (>20-40 kg)
Bravecto 1400 mg chewable tablets for very large dogs (>40-56 kg) Fluralaner

Dosage for each species, route of administration and method of administration

For oral use.

Bravecto should be administered according to the following table (corresponding to a dose of 25.56 fluralaner/kg body weight according to the body weight band):

For dogs over 56 kg body weight, use a combination of two tablets that best matches the weight of the animal.
The chewable tablets should not be broken or divided.
Bravecto chewable tablets should be administered at or around feeding time.
Bravecto is a chewable tablet and is well tolerated by most dogs. If the tablet is not taken voluntarily by the dog, it can also be administered with food or directly into the oral cavity.
The dog should be observed during administration to confirm that the tablet is swallowed.

Treatment regimen:

For optimal control of flea infestation, the veterinary medicinal product can be administered at 12-week intervals. For optimal control of tick infestation, the timing of re-administration depends on the tick species. See section 4.

Withdrawal period: Not applicable.

Special precautions for storage:

Keep out of the sight and reach of children. Do not use this veterinary medicinal product after the expiry date stated on the label. The expiry date refers to the last day of that month.

Special warnings

Special warnings for each target species:

To be exposed to fluralaner, the parasites must start feeding on the host; therefore, the risk of transmission of transmissible diseases cannot be excluded.

Special precautions for use